Study #2014-0533
A phase II study of anti-PD-1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer who have received prior chemotherapy with clinical response
MD Anderson Study Status
Not Accepting
Treatment Agent
Pembrolizumab
Description
This phase II trial studies how well pembrolizumab works in treating patients with stage IV inflammatory breast cancer or triple-negative breast cancer that has spread to other places in the body (metastatic) or has come back (recurrent), and who have achieved clinical response or stable disease to prior chemotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Peau d'Orange, Progesterone Receptor Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Inflammatory Breast Carcinoma, Triple-Negative Breast Carcinoma
Study phase:
Phase II
Physician name:
Bora Lim
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-866-395-2548
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.